SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 230 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,860,341 | -36.0% | 67,477 | -30.2% | 0.01% | -35.0% |
| Q2 2023 | $2,906,682 | -15.6% | 96,696 | +1.7% | 0.02% | -20.0% |
| Q1 2023 | $3,444,567 | -1.5% | 95,075 | -3.0% | 0.02% | -7.4% |
| Q4 2022 | $3,497,693 | +105283.9% | 98,057 | 0.0% | 0.03% | -3.6% |
| Q3 2022 | $3,319 | -99.9% | 98,057 | -0.8% | 0.03% | +16.7% |
| Q2 2022 | $2,859,000 | -10.9% | 98,875 | -0.4% | 0.02% | +20.0% |
| Q1 2022 | $3,208,000 | +1.6% | 99,256 | -8.4% | 0.02% | +17.6% |
| Q4 2021 | $3,159,000 | +9.3% | 108,346 | 0.0% | 0.02% | 0.0% |
| Q3 2021 | $2,890,000 | -13.4% | 108,346 | 0.0% | 0.02% | -15.0% |
| Q2 2021 | $3,336,000 | -3.3% | 108,346 | -17.8% | 0.02% | -9.1% |
| Q1 2021 | $3,449,000 | -8.4% | 131,749 | -12.0% | 0.02% | -24.1% |
| Q4 2020 | $3,766,000 | +33.5% | 149,687 | +10.6% | 0.03% | +26.1% |
| Q3 2020 | $2,822,000 | +1.1% | 135,391 | +15.2% | 0.02% | -11.5% |
| Q2 2020 | $2,791,000 | +32.0% | 117,496 | 0.0% | 0.03% | +4.0% |
| Q1 2020 | $2,114,000 | -24.1% | 117,496 | 0.0% | 0.02% | +47.1% |
| Q4 2019 | $2,787,000 | -24.2% | 117,496 | -12.2% | 0.02% | -32.0% |
| Q3 2019 | $3,677,000 | -3.8% | 133,796 | +15.9% | 0.02% | -19.4% |
| Q2 2019 | $3,821,000 | +15.2% | 115,464 | +22.0% | 0.03% | +3.3% |
| Q1 2019 | $3,317,000 | +17.4% | 94,664 | +11.3% | 0.03% | +25.0% |
| Q4 2018 | $2,826,000 | +54.8% | 85,067 | +134.6% | 0.02% | +84.6% |
| Q3 2018 | $1,826,000 | -8.4% | 36,264 | +8.8% | 0.01% | -7.1% |
| Q2 2018 | $1,994,000 | +30.7% | 33,316 | 0.0% | 0.01% | +27.3% |
| Q1 2018 | $1,526,000 | -21.1% | 33,316 | -31.3% | 0.01% | -15.4% |
| Q4 2017 | $1,933,000 | +52.3% | 48,516 | +53.0% | 0.01% | +160.0% |
| Q3 2017 | $1,269,000 | +14.1% | 31,716 | +22.9% | 0.01% | -44.4% |
| Q2 2017 | $1,112,000 | +1.5% | 25,800 | -26.3% | 0.01% | -10.0% |
| Q1 2017 | $1,096,000 | +24.0% | 35,000 | 0.0% | 0.01% | +11.1% |
| Q4 2016 | $884,000 | +2.1% | 35,000 | 0.0% | 0.01% | 0.0% |
| Q3 2016 | $866,000 | +81.6% | 35,000 | +49.6% | 0.01% | +80.0% |
| Q2 2016 | $477,000 | +33.6% | 23,400 | 0.0% | 0.01% | +25.0% |
| Q1 2016 | $357,000 | +13.7% | 23,400 | 0.0% | 0.00% | +33.3% |
| Q4 2015 | $314,000 | -41.5% | 23,400 | -38.9% | 0.00% | -40.0% |
| Q3 2015 | $537,000 | -27.6% | 38,300 | -12.4% | 0.01% | 0.0% |
| Q2 2015 | $742,000 | – | 43,700 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |